title: High-dose lidocaine does not affect defibrillation efficacy: implications for defibrillation mechanisms.
abstract: This study assessed the effect of low (10 mg.kg-1.h-1) and very high (18 mg.kg-1.h-1) doses of lidocaine on defibrillation energy requirements (DER) to relate changes in indexes of sodium-channel blockade with changes in DER values using a dose-response study design. In group 1 (control; n = 6 pigs), DER values were determined at baseline and during treatment with 5% dextrose in water (D5W) and with D5W added to D5W. In group 2 (n = 7), DER values were determined at baseline and during treatment with low-dose lidocaine followed by high-dose lidocaine. In group 3 (n = 3), DER values were determined at baseline and high-dose lidocaine. Group 3 controlled for the order of lidocaine treatment with the addition of high-dose lidocaine after baseline. DER values in group 1 did not change during D5W. In group 2, low-dose lidocaine increased DER values by 51% (P = 0.01), whereas high-dose lidocaine added to low-dose lidocaine reduced DER values back to within 6% of baseline values (P = 0.02, low dose vs. high dose). DER values during high-dose lidocaine in group 3 also remained near baseline values (16.2 +/- 2.7 to 12.9 +/- 2.7 J), demonstrating that treatment order had no impact on group 2. Progressive sodium-channel blockade was evident as incremental reduction in ventricular conduction velocity as the lidocaine dose increased. Lidocaine also significantly increased ventricular fibrillation cycle length as the lidocaine dose increased. However, the greatest increase in DER occurred when ventricular fibrillation cycle length was minimally affected, demonstrating a negative correlation (P = 0.04). In summary, lidocaine has an inverted U-shaped DER dose-response curve. At very high lidocaine doses, DER values are similar to baseline and tend to decrease rather than increase. Increased refractoriness during ventricular fibrillation may be the electrophysiological mechanism by which high-dose lidocaine limits the adverse effects that low-dose lidocaine has on DER values. However, there is a possibility that an unidentified action of lidocaine is responsible for these effects.
authors.affiliation: University of Georgia College of Pharmacy, Augusta, USA.
authors.forename: M R
authors.initials: MR
authors.lastname: Ujhelyi
authors.forename: J J
authors.initials: JJ
authors.lastname: Sims
authors.forename: A W
authors.initials: AW
authors.lastname: Miller
mesh_terms: D000818:Animals; D004305:Dose-Response Relationship, Drug; D004554:Electric Countershock; D004594:Electrophysiology; D006321:Heart / Q000503:physiopathology; D006329:Heart Conduction System / Q000503:physiopathology; D008012:Lidocaine / Q000008:administration & dosage* / Q000494:pharmacology; D009994:Osmolar Concentration; D013552:Swine; D013997:Time Factors; D014693:Ventricular Fibrillation / Q000503:physiopathology*; D016276:Ventricular Function
chemical_list: D008012:Lidocaine